Company intelligence / Profile preview

Moberg Pharma AB

Ownership: Private
Employees: ~9
Development stage: Other

Overview

MOB-015 has been granted marketing authorization in 13 EU countries. The product demonstrated superior levels of mycological cure (76% vs up to 42% for comparators) in Phase 3 trials. However, in December 2024, MOB-015 did not meet the primary endpoint in the North American Phase 3 study using 8 weeks of daily dosing. The product is currently sold in Sweden under the brand name Terclara.[7][8]

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (topical formulations)
Industry: Biotech

Drug pipeline

12 assets

Kerasol

11 more assets in the full pipeline.

Partnerships

Bayer (Europe)Cipher Pharmaceuticals (Canada)

Beyond the preview

Go deeper on Moberg Pharma AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moberg Pharma AB.